Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

The company’s lead indication area is cardiogenic shock (which is a severe form of heart failure) with istaroxime. Windtree ...

This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The primary endpoint will evaluate the difference in weight loss of nimacimab ...

Bibb County Schools are currently in phase three of a four-phase assessment plan, with officials gathering community input ...

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enr ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...

Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...

BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 ...

Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsEdward Berg - Senior Vice President and ...

In the company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10-K and the third quarter ... update designed to further accelerate ...

SHIELD II Enrollment Completion Expected in December 2024 with Top-Line Results Anticipated in First Quarter of 2025 PETACH TIKVA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ...

Following the abrupt closure of the University of the Arts in June, Julee Gard calculated financial health scores for 13 ...